

can be designed for modification at the local level to ensure compliance with local law. I have no doubt that solutions to the complicated medical and legal problems associated with the prehospital resuscitation decision-making process can be found. I invite members of the organization to participate in the process of developing such guidelines to ensure that the rights and interests of all parties in the system are respected and protected.

#### References

1. American Heart Association: Standards and guidelines for cardiopulmonary resuscitation and emergency cardiac care. *JAMA* 1986;255:2841.
2. *Ibid.* 2980-2981.
3. *Ibid.* 2980.
4. *Ibid.* 2980-2981.

Richard A. Lazar  
Portland, Oregon

#### To The Editor:

It was flattering to be the subject of such an extensive commentary by Dr. Moles (Vol 5:271-272). Close reading of this "critical review" reveals three distinct types of comments. We are pleased to respond to each of them.

I. Issues that were explicitly noted and discussed in the original article in Vol 5:

A. "No rationale or criteria are given for the selection of the pacemaker electrode combination in each subject..."

However, page 146, paragraph 1 notes explicitly that "the particular pacer electrode combination selected for each subject was determined by a previous TCP study in which moderate to severe discomfort was experienced at capture threshold."

B. "Unblinded exposure in the N<sub>2</sub>O trial...introduces a placebo-type bias; this error could and should be quantified in a comparative trial blinded by use of cylinder medical air delivered through an identical system."

Again, the issue is overtly noted. Page 146, paragraph 3 states, "...pilot trials demonstrated that subjects invariably distinguished the nitrous oxide gas from a control gas. As a result, these trials were unblinded." Then once more, on page 147, paragraph 6, we note, "...limitations to the present study...the study was unblinded due to the ability of subjects to distinguish the nitrous oxide gas from the 'control' gas."

C. Dr. Moles states, (page 272, Paragraph 1) "Prior exposure to N<sub>2</sub>O, providing previous knowledge of effect, unequivocally (italics ours) compounds this error with a second conditioned bias favoring N<sub>2</sub>O..."

But page 148, paragraph 1, specifically deals with this question. "...each subject had participated in a previous TCP (not nitrous oxide) study and was familiar with the technique of TCP...Previous (TCP) experience should not have introduced a consistent bias favoring the ni-

trous oxide or room air trial." Actually, very few of the subjects had previously experienced nitrous oxide and how this would affect their pain perception is far from "unequivocal," it is extremely speculative.

D. Dr. Moles takes us to task for "omitting comment on capture verification in the N<sub>2</sub>O trials." Careful reading of page 146, paragraph 2, however would have revealed "Electrocardiographic (EKG) documentation of capture was required for all trials."

II. A second category of comments may be grouped under the rubric "comments that are factually wrong." Space limitations preclude an inclusive listing, but we note a few.

A. "The range given for the PVAS (Pain visual analog scale) extends only to 8, which seems paradoxical."

There is nothing paradoxical about it. The upper range of responses was indeed 8.0. The maximum possible response was 10.0 representing very severe pain. Clearly, no subject considered his pain to be "very severe" even if he elected to have his pacing discontinued. This is neither surprising or paradoxical.

B. "The last sentence of the methods section seems far from exact!"

Really? The sentence in question states, "Where appropriate, preferences for the respective trials were compared with the Chi-Square or Fisher's Exact Test." As frequent readers of medical journals already know, this is a commonly used phraseology when one of two similar statistical tests is more appropriate than the other due to cell frequency. As always, Fisher's Exact Test was utilized for analysis when cell size was low, Chi-Square in the other cases.

C. None of the statistical criticisms appear valid. The assertion (page 272, paragraph 6) states, "The pacer time trial reports means of 22.4 and 23.8 seconds....These data are not normally distributed and the t-test is invalid."

There are two errors in this statement. First, the distribution, while obviously not a perfect normal distribution, is, in fact, not markedly skewed. Further, the t-test utilized is quite robust to violation of normality assumption when  $n=18$ , as it did here.

III. The third type of comments deal with question and definitions that were not quite clear to Dr. Moles. We are happy to clarify them, although it seems likely that they would have been a source of ambiguity to most readers. The capture threshold was expressed as  $103 \pm 37$  ma—this does, indeed, refer to the entire range (not the standard deviation) of the responses. We did not report whether the 15 (out of 18) subjects expressing a preference for nitrous oxide was statistically significant as this type of two-tailed exact binomial test is almost trivial and likely to be misleading. For what it is worth, the value is indeed significant at  $p .0075$ . "Premature termination" means that the sub-

ject asked us to stop TCP due to discomfort. "Prolongation time" refers to how much longer a subject could be paced with nitrous than without. We are not surprised that the other peer reviewers had no difficulty understanding these concepts, even without explicit definitions. And yes, the consent from explicitly mentioned in our article was (like the study itself) approved by the University of Pittsburgh IRB.

Finally we would just note the remarkably eclectic concatenation of "confounding variables" that we are berated for not specifically excluding: "psychotropics; fasting; food; and alcohol intake; exercise; circadian endocrine/endorphin variations, e.g., menstruation and endomorphin variations...". We will allow PDM's readership to reach their own conclusion regarding the criticality of such factors in a TCP study. And, we hope that our comments will similarly allow them to evaluate the overall validity of Dr. Moles' critique.

Michael B. Heller, MD  
Associate Professor of Medicine  
University of Pittsburgh  
Pittsburgh, Pennsylvania

#### To The Editor:

These comments are in reference to the recent article by Schwartz et al on the "Role of the Physician in a Helicopter Emergency Medical Service," (Vol 5,1) and the follow-up correspondence from Morgan (Vol 5,2). Dr. Morgan seems convinced that patients might be treated by non-physicians for serious or minor illnesses, particularly in a helicopter EMS.

It is well-established in American medicine that physician assistants and nurse practitioners are able to provide basic medical care. Indeed, such properly licensed and supervised individuals are authorized legally to administer such care, in both the hospital and outpatient settings. Additionally, the medical profession has decided that specially trained paramedics are the appropriate health care providers for the great bulk of EMS patients, when associated with physician consultation for medical control and treatment protocol development.

Clearly, there are some complicated EMS cases which might necessitate the intervention of a physician during flight, but as Schwartz and his colleagues so nicely show in their paper, these cases remain a distinct minority. The dispatch of physicians on helicopters for every EMS call would take physicians away for areas of greater need, e.g., busy emergency departments with high acuity patient loads. It is with this reasoning in mind that prehospital medical care has evolved to its present form, with EMT-I, EMT-D, and EMT-P staff providing care for patients outside the hospital. As with so many other issues, more is not necessarily better; so it is with the presence of physicians on the great majority of helicopter EMS flights.


Steven J. Rottman, Jr., MD  
Medical Director  
UCLA Center for Prehospital Care  
Los Angeles, California



# SUN BELT MEDICAL SUPPLY

## "Emergency Medication Specialists"

- Very Aggressive Pricing ■ Orders Shipped Same Day
- Merchandise Always in Stock



### EMERGENCY PREFILLED

- 001 Aminophylline Syringe 250mg, 10ml
- 002 Aminophylline Syringe 500mg, 20 ml
- 003 Atropine Syringe 1mg, 10mg
- 004 Bretylium Tosylate Syringe 500mg, 10ml
- 005 Calcium Chloride Syringe 1gm, 21 gauge
- 006 Calcium Chloride Syringe 1gm, 18 gauge
- 007 Dextrose Syringe 25gm, 50%, 50ml
- 008 Diphenhydramine Syringe 50 mg, 1ml
- 009 Dopamine Syringe 200 mg, 5ml
- 010 Dopamine Syringe 400mg, 10ml
- 011 Dopamine Syringe 800mg, 20ml
- 012 Epinephrine Syringe 1:1,000, 1mg, 1ml
- 013 Epinephrine Syringe 1:10,000, 0.3mg, 3ml
- 014 Epinephrine Syringe 1:10,000, 1mg, 10ml, 21 gauge
- 015 Epinephrine Syringe 1:10,000, 1mg, 10ml, 18 gauge
- 016 Ephedrine Syringe 50mg, 10ml
- 017 Furosemide Syringe 20mg, 2ml
- 018 Furosemide Syringe 40mg, 4ml
- 019 Furosemide Syringe 60mg, 6ml
- 020 Furosemide Syringe 80mg, 8ml
- 021 Furosemide Syringe 100mg, 10ml
- 022 Isoproterenol Syringe 1mg, 5ml
- 023 Isoproterenol Syringe 2mg, 10ml

- 024 Lidocaine Syringe 1% 50mg, 5ml
- 025 Lidocaine Syringe 1% 100mg, 10ml
- 026 Lidocaine Syringe 2% 100mg, 5ml
- 027 Lidocaine Syringe 20% 1gm, 5ml
- 028 Lidocaine Syringe 20%, 2gm, 10ml
- 029 Magnesium Sulphate Syringe 5gm, 10ml
- 030 Naloxone Syringe 0.4mg, 1ml
- 031 Naloxone Syringe 0.8mg, 2ml
- 032 Naloxone Syringe 2mg, 2ml
- 033 Procainamide Syringe 1gm, 10ml
- 034 Sodium Bicarbonate Syringe 4.2%, 10ml
- 035 Sodium Bicarbonate Syringe 7.5%, 50ml
- 036 Sodium Bicarbonate Syringe 8.4%, 50ml
- 037 Sodium Bicarbonate Syringe Pediatric 8.4%, 10ml
- 038 Verapamil Syringe 5mg, 2ml
- 039 Verapamil Syringe 10mg, 4ml

### IV SOLUTIONS

- 040 Dextrose 5%, 250ml
- 041 Dextrose 5%, 500ml
- 042 Dextrose 5%, 1000ml
- 043 Sodium Chl, 0.9%, 250ml
- 044 Sodium Chl, 0.9%, 500ml
- 045 Sodium Chl, 0.9%, 1000ml
- 046 Lactated Ringers 250ml

- 047 Lactated Ringers 500ml
- 048 Lactated Ringers 1000ml

### MISCELLANEOUS DRUGS

- 049 Iprcac Syrup, 30ml bottle
- 050 Nitro Tablets, 1/150, bottle 100
- 051 Proventil, 2.5 mg vial
- 052 Thiamine, Tubex Syringe, 100mg
- 053 Dexamethasone 5ml, 20mg
- 054 Dexamethasone 10ml, 100mg
- 055 Brethine, 1mg Aapule
- 056 Dextrostix Strips
- 057 Nitrolingual Spray 13.8gm
- 058 Procardia 10mg., Unit dose capsule

### IV CATHETERS, SETS & TUBING

- 059 IV Catheter 16 gauge, 1 1/4"
- 060 IV Catheter 18 gauge, 1 1/4"
- 061 IV Catheter 20 gauge, 1 1/4"
- 062 IV Catheter 22 gauge, 1 1/4"
- 063 IV Catheter 24 gauge, 3/4"
- 064 IV Catheter 14 gauge, 5 1/2"
- 065 IV Catheter 14 gauge, 2"
- 066 IV Catheter 16 gauge, 8"
- 067 IV Administration Sets Mini-Drip
- 068 IV Administration Sets Macro-Drip
- 069 IV Extension Sets, 30", no Y-Sites
- 070 IV Extension Sets, 30", 2 Y-Sites
- 071 Blood Solution Sets Y-Type, 10dr/ml

**We pledge to save you BIG dollars on your drug purchases and make your transition from the hospital as smooth as possible.**

**"Emergency Medication is our only Business!"**

**Call 1-800-476-5761 for our great pricing!**